V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214065 | 20080414 | 1.67 | 97 | Curative (C) | 2017-05-02 | 2017-05-20 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101071623 |
| 20214066 | 20080415 | 1.6 | 67 | Curative (C) | null | 2018-10-28 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101842137 |
| 20214067 | 20080416 | 1.63 | 78 | Disease modification (D) | 2017-03-08 | 2017-03-08 | LANREOTIDE | N | N | LANREOTIDE | 100726418 |
| 20214068 | 20080417 | 1.7 | 74.8 | null | 2017-09-22 | 2017-10-09 | GO2 TRIAL | 1 | N | TRIAL | 100815352 |
| 20214069 | 20080418 | 1.71 | 64.8 | Curative (C) | null | 2018-05-17 | FLUOROURACIL + MITOMYCIN + RT | N | N | FLUOROURACIL + MITOMYCIN + RT | 100599960 |
| 20214070 | 20080419 | 0 | 45.8 | 02 | 2019-12-18 | 2019-12-18 | LANREOTIDE | N | N | LANREOTIDE | 101350248 |
| 20214071 | 20080420 | 1.78 | 59 | Neo-adjuvant (N) | 2017-08-30 | 2017-08-30 | Imatinib 400mg | 02 | N | IMATINIB | 100156539 |
| 20214072 | 20080421 | 1.71 | 73.3 | Curative (C) | 2018-06-19 | 2018-08-13 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100901622 |
| 20214073 | 20080422 | 1.76 | 95.8 | Curative (C) | 2015-12-30 | 2016-01-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100561261 |
| 20214074 | 20080423 | 1.8 | 92 | null | null | 2016-10-04 | IMATINIB | 02 | null | IMATINIB | 100596396 |
| 20214076 | 20080425 | 1.83 | 62.1 | Palliative (P) | 2019-07-07 | 2019-08-26 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100385443 |
| 20214077 | 20080426 | 1.72 | 0 | Neo-adjuvant (N) | 2019-12-20 | 2020-01-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100857754 |
| 20214079 | 20080427 | 1.77 | 83 | null | 2018-12-05 | 2018-12-05 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 100349227 |
| 20214080 | 20080428 | 1.69 | 61.2 | Neo-adjuvant (N) | 2017-02-20 | 2017-02-20 | Imatinib 400mg | 01 | N | IMATINIB | 100942633 |
| 20214081 | 20080429 | 1.63 | 72 | Palliative (P) | 2019-09-04 | 2019-09-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100828967 |
| 20214083 | 20080430 | 1.91 | 107.8 | Curative (C) | 2019-04-15 | 2019-06-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | Y | FLUOROURACIL + MITOMYCIN + RT | 101634233 |
| 20214085 | 20080432 | 1.8 | null | Palliative (P) | 2018-07-24 | 2018-07-24 | IMATINIB | 02 | N | IMATINIB | 100849897 |
| 20214086 | 20080433 | 1.56 | 69.3 | Curative (C) | 2016-09-26 | 2016-10-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101059181 |
| 20214087 | 20080434 | 1.61 | 0 | Curative (C) | 2017-09-17 | 2017-09-29 | HCX | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101474632 |
| 20214089 | 20080436 | 1.68 | 55.6 | Curative (C) | 2016-12-12 | 2016-12-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100835127 |
| 20214090 | 20080437 | 1.49 | 84 | Palliative (P) | 2018-10-20 | 2018-11-19 | Trial Unspecified | 01 | N | TRIAL | 101177759 |
| 20214091 | 20080438 | 1.59 | 81 | Palliative (P) | 2018-09-16 | 2018-10-03 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101349148 |
| 20214093 | 20080439 | 0 | 56.2 | null | 2020-02-23 | 2020-02-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 100660656 |
| 20214094 | 20080440 | 1.64 | 69.9 | null | 2019-09-05 | 2019-09-12 | LANREOTIDE | 02 | N | LANREOTIDE | 101389299 |
| 20214095 | 20080441 | 1.67 | 55.5 | null | 2020-03-13 | 2020-05-27 | Cape+Cisplatin+Trastuzumab Load | 02 | null | IMATINIB | 100250165 |
| 20214096 | 20080442 | 0 | 69.45 | null | 2017-08-21 | 2017-09-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 100042053 |
| 20214099 | 20080443 | 1.53 | 61.6 | Palliative (P) | 2017-12-02 | 2017-12-07 | Trial Unspecified | Y | N | TRIAL | 100584104 |
| 20214100 | 20080444 | 1.63 | 68.9 | Palliative (P) | 2017-08-07 | 2017-08-23 | HCX (Cape + Cisp + Tras) - Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101793730 |
| 20214101 | 20080445 | null | 70.4 | Disease modification (D) | 2017-08-09 | 2017-08-09 | Fluorouracil+Mitomycin+RT (Bladder) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100629541 |
| 20214102 | 20080446 | 1.67 | 53.6 | Palliative (P) | null | 2012-07-07 | null | null | N | TRIAL | 100134483 |
| 20214104 | 20080447 | 1.63 | 65.5 | Palliative (P) | 2021-01-02 | 2021-01-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101333637 |
| 20214105 | 20080448 | 1.7 | 77 | Palliative (P) | 2020-07-14 | 2020-08-01 | Trial Unspecified | Y | N | TRIAL | 100070885 |
| 20214109 | 20080450 | 1.67 | 58.3 | null | 2018-11-08 | 2018-12-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 100062839 |
| 20214110 | 20080451 | 1.65 | 74.7 | Curative (C) | 2018-05-04 | 2018-05-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100238583 |
| 20214111 | 20080452 | null | 72 | Palliative (P) | 2016-03-13 | 2016-03-19 | LANREOTIDE | 02 | N | LANREOTIDE | 101210760 |
| 20214112 | 20080453 | 1.73 | 86 | Palliative (P) | 2019-02-10 | 2019-03-19 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100119981 |
| 20214114 | 20080454 | 1.76 | 81.9 | Curative (C) | 2018-04-24 | 2018-05-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101296524 |
| 20214115 | 20080455 | null | 85.3 | Curative (C) | 2016-12-03 | 2016-12-30 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100375995 |
| 20214116 | 20080456 | 1.73 | 0 | null | 2016-02-03 | 2016-02-03 | LANREOTIDE | 02 | N | LANREOTIDE | 100011439 |
| 20214117 | 20080457 | 1.77 | 56.7 | Palliative (P) | 2018-01-12 | 2018-01-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101422466 |
| 20214118 | 20080458 | 1.72 | 60 | Neo-adjuvant (N) | 2018-02-06 | 2018-02-26 | TCX | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101749081 |
| 20214120 | 20080459 | 1.63 | 107.8 | Palliative (P) | null | 2019-05-27 | HCX | 02 | N | IMATINIB | 100552320 |
| 20214121 | 20080460 | 1.6 | 79.8 | Palliative (P) | 2018-07-29 | 2018-08-03 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100736965 |
| 20214122 | 20080461 | 1.64 | 80.3 | Palliative (P) | 2018-06-27 | 2018-07-03 | HCX (Cape + Cisp + Tras) - Load | 01 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100718454 |
| 20214123 | 20080462 | 1.68 | 66.5 | Palliative (P) | null | 2018-07-07 | Trial Unspecified | 1 | N | TRIAL | 101102612 |
| 20214124 | 20080463 | 1.68 | 73.6 | Curative (C) | 2019-06-04 | 2019-06-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100931845 |
| 20214127 | 20080465 | 1.7 | 71 | Palliative (P) | 2021-11-28 | 2021-12-17 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101516461 |
| 20214129 | 20080466 | 1.68 | 88.6 | Neo-adjuvant (N) | 2017-01-11 | 2017-01-24 | CAPECITABINE + CISPLATIN + Trastuzumab | null | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100041702 |
| 20214130 | 20080467 | 1.48 | 43.45 | Curative (C) | 2019-05-12 | 2019-05-22 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100660410 |
| 20214133 | 20080469 | 1.65 | 65 | Palliative (P) | 2019-04-06 | 2019-04-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100855387 |